Evidence map›Paper›PMID 34956455›Full record

ArticleAmerican journal of translational research2021

Metformin reduces pleural fibroelastosis by inhibition of extracellular matrix production induced by CD90-positive myofibroblasts.

Yoichiro Aoshima, Yasunori Enomoto, Atsuki Fukada, Yuki Kurita, Sayomi Matsushima, Shiori Meguro, Isao Kosugi, Hideya Kawasaki, Hiroaki Katsura, Tomoyuki Fujisawa and 5 more

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Pulmonary fibroelastosis - A review.Matrix biology : journal of the International Society for Matrix Biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Yoichiro AoshimaDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Yasunori EnomotoDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Atsuki FukadaDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Yuki KuritaDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Sayomi MatsushimaDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Shiori MeguroDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Isao KosugiDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Hideya KawasakiDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Hiroaki KatsuraLaboratory for Lung Development and Regeneration, Riken Center for Biosystems Dynamics Research (BDR) Kobe 650-0047, Japan.
Tomoyuki FujisawaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Noriyuki EnomotoSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Yutaro NakamuraSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Naoki InuiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Takafumi SudaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Toshihide IwashitaDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine Shizuoka 431-3192, Japan.
Shizuoka University · JPRIKEN Center for Biosystems Dynamics Research · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metformin, an AMP-activated protein kinase activator used to treat diabetes mellitus, has recently attracted attention as a promising anti-fibrotic agent. However, its anti-fibrotic effects on pleural fibroelastosis remain unknown. We induced mouse pleural fibroelastosis by intra-pleural coadministration of bleomycin and carbon and evaluated its validity as a preclinical model for human pleural fibrosis. We assessed the expression of the myofibroblast surface marker CD90 in the fibrotic pleura and the effects of metformin

Indexed as

Metforminmyofibroblastpleural fibrosispleuroparenchymal fibroelastosis

Identifiers

PMID34956455
PMCPMC8661163
OpenAlexW4206860440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.